Frontotemporal Dementia (FTD) - Pipeline Insight, 2020

DelveInsight’s, “Frontotemporal Dementia – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage
Frontotemporal Dementia Understanding
Frontotemporal Dementia: Overview
Frontotemporal dementia (FTD) is a clinically, neuroanatomically, and pathologically heterogeneous group of neurodegenerative diseases that share a propensity to target the frontal and temporal lobes of the brain. Despite often being considered as a rare disease, FTD is probably the most common form of dementia experienced in people under the age of 60, with an estimated lifetime risk of 1 in 742.

The FTD spectrum encompasses three canonical clinicoanatomical variant syndromes, classified according to their leading features. Behavioral variant FTD (bvFTD), the commonest of themajor FTD phenotypes, presents with progressive declinein emotional reactivity and interpersonal and executive skills, associated with a variable profile of frontotemporal atrophy. Semantic variant PPA (svPPA) presents with loss of vocabulary and ultimately degrades semantic knowledge of sensory objects and nonverbal concepts as well as words; it is characteristically associated with focal atrophy chiefly affecting the left anteromesial temporallobe. Nonfluent/agrammatic variant PPA (nfvPPA) presents with impaired motor speech production and/or sentence construction, associated with relatively focal, predominantly left anterior perisylvian atrophy.

Accurate diagnosis of FTD syndromes is challenging: clinician’s experience of these diseases is often limited, and presentations dominated by personality change or aphasia are readily misinterpreted as psychiatric illness, stroke, or other conditions, especially in the earlier stages. On the other hand, “overinterpretation” of brain atrophy on neuroimaging sometimes leads to a spurious diagnosis of FTD. A detailed neurological examination is required to identify associated extrapyramidal or motor neuron deficits that frequently develop during the course of the disease. Neuroimaging, ideally with magnetic resonance imaging (MRI) and interpreted by an experienced observer, is essential to corroborate the bedside impression, and, where available, neuropsychological assessment is very valuable, to quantify key deficits and their evolution over time (which may be decisive in clinically ambiguous cases) and also to capture associated cognitive deficits that help to define the phenotype.

No treatments have currently been shown to alter the underlying disease process in any FTD syndrome. Management of FTD begins with provision of accurate information about the nature of the illness to the patient, family members, caregivers, and relevant health professionals There are several excellent online resources (for example: and access to a local or national lay support group oriented to FTD ( can be a transformative source of practical advice and informal counseling. Practical and emotional support and regular respite for caregivers are integral to successful management, but are easily overlooked. Neuroleptic medications may be required to manage psychosis, intractable aggression, or intrusive compulsions, though care is needed, as patients with FTD are at risk of significant extrapyramidal side effects, even with newer generation agents, in this situation, low-dose risperidone or quetiapine is favoured, with close clinical monitoring.

Frontotemporal Dementia Emerging Drugs Chapters
This segment of the Frontotemporal Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Frontotemporal Dementia Emerging Drugs
• AL001: Alector
AL001 is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the blood stream to increase the levels of PGRN in the brains of FTD-GRN patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from FDA for the treatment of FTD in 2018.

Further product details are provided in the report……..
Frontotemporal Dementia: Therapeutic Assessment
This segment of the report provides insights about the different Frontotemporal Dementia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Frontotemporal Dementia
There are approx. 3+ key companies which are developing the therapies for Frontotemporal Dementia. The companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.

• Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Frontotemporal Dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal Dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal Dementia drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia.
• In May 2020, AbbVie announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
Frontotemporal Dementia Report Insights
• Frontotemporal Dementia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Frontotemporal Dementia Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Frontotemporal Dementia drugs?
• How many Frontotemporal Dementia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal Dementia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal Dementia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Frontotemporal Dementia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Alector
• Avid Radiopharmaceuticals
• Passage Bio
• AcuraStem
• TauRx Pharmaceuticals

Key Products
• AL001
• Florbetapir 18F
• PBFT02
• AS202

Executive Summary
Frontotemporal Dementia: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Frontotemporal Dementia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Frontotemporal Dementia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Frontotemporal Dementia Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
AL001: Alector
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
Florbetapir 18F: Avid Radiopharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
AL101: Alector
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
PBFT02: Passage Bio
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Frontotemporal Dementia Key Companies
Frontotemporal Dementia Key Products
Frontotemporal Dementia - Unmet Needs
Frontotemporal Dementia - Market Drivers and Barriers
Frontotemporal Dementia - Future Perspectives and Conclusion
Frontotemporal Dementia Analyst Views
Frontotemporal Dementia Key Companies
Table 1 Total Products for Frontotemporal Dementia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Frontotemporal Dementia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings